Feasibility Study of Pyrrolitinib-Based Dual-Target Therapy for Neoadjuvant Treatment of HER2-Positive Breast Cancer Patients
Feng Zhao, Hongzhen Zhang · 2024
Read Feasibility Study of Pyrrolitinib-Based Dual-Target Therapy for Neoadjuvant Treatment of HER2-Positive Breast Cancer Patients by Feng Zhao, Hongzhen Zhang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11614581.txt.
Description
Feng Zhao and Hongzhen Zhang test an added drug for aggressive HER2 positive breast cancer. Dual targeted therapy is standard, yet some tumors slip control. Twenty eight patients at a Shandong hospital got the dual regimen plus pyrrolitinib, a kinase blocker, as intensified pre surgery treatment.
Tumors shrank markedly on examination during the course. No serious adverse reactions appeared in the series. The authors judge the add on feasible, safe, and promising for deeper responses. They also stress the limits: one center, few patients, no comparison arm. Larger controlled studies must confirm the hint before practice changes.
Catalog record
| CREATOR | Feng Zhao, Hongzhen Zhang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |